Strong growth masked by margin compression and cash flow decline
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Hit revenue/PAT growth targets; missed implicit margin guidance (21.6% vs. 22-23% range). Cash flow signal concerning.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong 20% YoY growth and 39% PAT jump validate core business momentum across 8 consecutive quarters. However, gross and EBITDA margins compressed below prior 22-23% guidance (delivered 21.6%), and operating cash flow collapsed 82% QoQ due to working capital absorption. FDA Form 483 with 11 observations and vague peptide CDMO commercialization create near-term execution risk.
₹1560 Cr
Revenue · +20.3% YoY₹181.8 Cr
Reported PAT · +39.2% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Revenue grew 20% YoY to ₹1,560 Cr crossing ₹1,500 Cr for first time
METDelivered ₹1,560 Cr, +20.3% YoY matches claim exactly
PAT increased 39% to ₹181.8 Cr
METDelivered ₹181.8 Cr, +39.2% YoY PAT growth matches claim
Eighth consecutive quarter of sequential revenue growth
METQoQ revenue +5.6% confirmed; claim matches
EBITDA margins expected to sustain 22-23% range (prior guidance)
OVERSTATEDDelivered 21.6%, down 131 bps QoQ; below the 22-23% expected range
Operating cash flow positive, business fundamentals strong
MISSOperating cash flow collapsed to ₹65 Cr Q2 from ₹387 Cr Q1 (82% decline); working capital absorption increased
Peptide CDMO will be PAT positive on annual basis FY27 end
OVERSTATEDH2 peptide revenue projected at ₹109 Cr with cumulative EBITDA loss ~₹28 Cr; still loss-making, PAT profitability uncertain
Gross margins remain healthy despite input cost inflation
OVERSTATEDGross margin 64.4%, down 134 bps YoY and 126 bps QoQ due to cost pressures
FDA inspection observations addressable, no impact on business
PartialForm 483 with 11 observations, most on process/control/recruitment/documentation; no timeline certainty despite 15-day response window
Earnings quality
What changed since the last call
Margin guidance implicitly missed
DowngradePrior: 22-23% EBITDA margin expected to continue. Delivered: 21.6%, down 131 bps QoQ. West Asia conflict cited; recovery timing vague.
Cash flow trajectory deteriorated
DowngradeOperating cash flow ₹65 Cr (Q2) vs. ₹387 Cr (Q1) and ₹194 Cr (Q2 FY26). Working capital increase and capex surge absorbed cash; concern on conversion.
Capex trajectory increased
UpgradePrior: ₹600 Cr FY27 guidance. Q1+Q2 spend: ₹2,194 Cr. Full-year capex now tracking ~₹2,000 Cr+ for next 3-4 years (INR2,000 crores planned), suggesting faster buildout.
Peptide CDMO commercialization slowed
DowngradePrior: PAT positive FY27 end. Delivered: H2 ₹109 Cr revenue, cumulative ₹28 Cr EBITDA loss. Senn Tides partnering with 2 major CDMO players for capacity support; revenue scaling lagged.
FDA approval pipeline broadened
Upgrade26 pending approvals from FDA (GGP, GPI, GLS). 3 products launching Q3/Q4 from GPI (2 controlled substances, 1 other). First-to-file ANDAs filed (3 sole FTF filed, litigation-based products).
Complex generics strategic focus deepened
UpgradeComplex generics now 47% of formulations revenue, up from 46% prior quarter. Multiple launches planned; expected to exceed 50% by medium term, offsetting legacy API/PFI headwinds.
The Q&A
Analysts pressed hard on FDA observations (risk to CDMO), cash flow decline (working capital absorption), margin recovery timeline (vague), and peptide CDMO targets (significantly behind). Management held firm on growth trajectory but largely evaded specific commitments, repeatedly saying 'we don't give guidance.' Tone was defensive on FDA but confident on underlying business momentum.
Peptide CDMO targets — Sajal Kapoor, Antifragile Thinking
PartialH2 heavier than H1, revenue between EBITDA neutrality and PAT neutrality depending on product mix. Hopeful to close near stated ambition in Q4 offtakes; PAT profitability committed for FY27 end.
Customer wins and capex contingency — Sajal Kapoor, Antifragile Thinking
DodgedCannot comment on customer details; under discussions. India Vizag facility capex not contingent on customers; proceeding with plan.
Gagillapur capacity and remediation — Tushar Mamudhane, Motilal Oswal
AnsweredGGP ~75% utilized. Typically 90-100 days for FDA response. 26 pending approvals; 3 products launching Q3/Q4 from GPI (2 controlled, 1 other). About 5 launches next 2 quarters.
Other expenses and remediation impact — Shashank Krishnakumar, Emkay Global
AnsweredFreight costs elevated by West Asia conflict; Q4 onwards will moderate significantly. Q3 will be similar to Q2 on cost pressures.
Complex generics share and trajectory — Shashank Krishnakumar, Emkay Global
AnsweredNot q-o-q variation; expect upward trajectory with new controlled substance launches Q3/Q4.
API/PFI segment growth and pricing — Rashmi Shetty, Dolat Capital
AnsweredPrimarily volume and pricing. LATAM geographic expansion contributing. With cost increases, prices also recovered.
Launch pipeline clarity — Rashmi Shetty, Dolat Capital
AnsweredFirst half: no launches. Next 2 quarters: 5 launches (generic Lumyrz, sodium oxybate, others). All complex generics, not FTF.
ADHD portfolio and quota management — Siddhesh Parekh, Unifi Mutual Fund
AnsweredPrimarily extended release products. Immediate release managed through quota allocation. Launches will maximize quota utilization.
ROCE and capex returns — Yash Mehta, Grit Securities
PartialInvestment hurdle rate is not to drag ROCE down. As utilization improves, ROCE will improve. GLS 25% utilized; Genome Valley and core consolidation at 25% ROCE. INR2,000 Cr capex will generate double-digit ROCE.
Margin evolution long-term — Yash Mehta, Grit Securities
PartialMargins on upward trajectory going forward. First-to-file wins expected in next 2.5-3 years. Margins expected on upward trajectory.
EBITDA margin guidance medium-term — Shreya Chatterjee, Ageless Capital
PartialEBITDA margin currently 21.6%, down 130+ bps due to West Asia conflict. Once settled, margin will improve. Price pass-on happening; no specific number given.
Capacity utilization ramp-up — Shreya Chatterjee, Ageless Capital
AnsweredGenome Valley 50% by Q4. Gagillapur ~75%, good room for product mix optimization and utilization.
FDA observations and approval timeline — Suhani Singh, ROS Capital
AnsweredAll 11 observations addressable; no data integrity or contamination issues. Good dialogue expected with FDA; quite positive on outcome. Business will continue and grow; growth not impacted.
Operating cash flow decline — Suhani Singh, ROS Capital
PartialTemporary. Q1 and Q2 together have capex and working capital absorption. Working capital up from 29% to 30%; inventory buildup in U.S. for safety stock and controlled substances. Will realign.
Gross margin trend and deleveraging — Sajal Kapoor, Antifragile Thinking
AnsweredCost base and business model changed. R&D increased significantly, U.S. operations added (high cost). U.S. footprint small; cost of employees higher. Significant deleveraging room exists.
Capex allocation and strategy — Sameer Baisiwala, Sakman Capital
AnsweredNot necessarily brownfield. Complex, oncology more new formulations. API/PFI downstream optimization. IT digitization also included. Multiple capex programs over next 3-4 years.
FTF and medium-term revenue — Sameer Baisiwala, Sakman Capital
Partial~2.5 years, 2.5-3 years away, subject to litigation. One product filing shortly, ~2.5-3 years away. U.S. filings ongoing; products will give short-to-medium term revenues.
Peptide CDMO customer engagement — Pehal Sharma, DD Capital
DodgedBound by confidentiality; cannot disclose. RFP to commercial translation takes time. Last 4 months highest inquiry; positive uptick visible with CDMO partners. Execution key over next few quarters.
Complex generics portfolio mix — Pehal Sharma, DD Capital
AnsweredMedium-path guidance is 50% formulations to be complex generics. Year-o-year basis ahead. Quarter-o-quarter some ups and downs; ahead of stated guidance. Will do >50% in medium term.
FDA approval and remediation timeline — Giovyanne, Individual Investor
AnsweredResponse due within 15 days detailing CAPA. Observations addressable. At this point, no re-inspection believed required; FDA will decide.
9 pending applications unblocking — Giovyanne, Individual Investor
AnsweredAfter EIR/VAI/NAI, FDA takes 30-90 days for approval. Generally 30-90 days after EIR. 9 filed from Gagillapur; 2 already transferred to U.S. facility, so only 7 remain there.
Guidance
FY27 growth continues; no numeric target
MediumMD stated 'we don't give guidance' but 'current rate of growth will continue.' Vague; no specific % or absolute target. YoY growth rate (20%) unlikely to sustain given margin pressure.
EBITDA margins on upward trajectory once cost pressures ease
LowPrior: 22-23% expected to continue. Delivered: 21.6%, 131 bps below. Recovery timeline vague; West Asia, input costs cited. Management says 'absolute profit will grow' but no margin target.
Gross margin recovery via price pass-through and volume leverage
LowCurrent pressure from input costs and freight (West Asia conflict). Price pass-on happening but lagged. No specific margin level guidance for H2.
INR2,000 Cr capex planned over next 3-4 years
MediumPrior: ₹600 Cr FY27. Q1+Q2 actual ₹219.4 Cr suggests full-year ₹400-500 Cr minimum. INR2,000 Cr multi-year for peptide CDMO (Zurich, India Vizag), API, oncology, IT digitization.
Risks the call surfaced
Regulatory and FDA
MediumGagillapur Form 483 with 11 observations (process, control, documentation). While management downplays, 15-day response window and FDA discretion on re-inspection creates uncertainty.
Financial Performance
HighGross margin 64.4% (down 134 bps YoY), EBITDA margin 21.6% (below 22-23% guidance). Operating cash flow collapsed to ₹65 Cr from ₹387 Cr Q1. PAT growth only 1% QoQ despite revenue +5.6%.
Business Development
MediumH2 peptide revenue projected at ₹109 Cr with cumulative EBITDA loss ₹28 Cr. Minimum annual target was ₹240 Cr; still loss-making, PAT profitability by FY27 end uncertain.
Operational Execution
MediumWorking capital absorbed to 30% of sales (up from 29% Q1). Operating cash flow ₹65 Cr Q2 vs. ₹387 Cr Q1 and ₹194 Cr Q2 FY26. Capex ₹130 Cr Q2 strains near-term cash conversion.
Strategic Risk
Low3 sole-filed FTF ANDAs pending approval subject to litigation outcomes. Timeline 2.5-3 years away; uncertain outcomes. Complex generics growth depends on regulatory approvals.
Management
Score 6/10. Selective transparency. Clear on financial metrics and facility details, but evasive on forward guidance ('we don't give guidance'). Confidentiality shields used on CDMO customer progress. Mixed track record. Hit Q2 revenue/PAT growth targets; missed implicit EBITDA margin guidance (21.6% vs. 22-23%). Peptide CDMO significantly lagging (₹109 Cr H2 vs. ₹240 Cr minimum target). 8 quarters sequential growth validates core execution.
1 · Q3/Q4 FY27
5 product launches (complex generics, controlled substances) to drive formulations portfolio
2 · Next 6 months
26 pending FDA approvals; first product launches from GGP expected
3 · 15 days
FDA response to Gagillapur Form 483 observations; potential for follow-up inspection
FDA Form 483 with 11 observations and vague peptide CDMO commercialization create near-term execution risk.
Informational and educational content only. Not investment advice.